Evidence map›Paper›PMID 29382351›Full record

ArticleParticle and fibre toxicology2018

The crystal structure of titanium dioxide nanoparticles influences immune activity in vitro and in vivo.

Rob J Vandebriel, Jolanda P Vermeulen, Laurens B van Engelen, Britt de Jong, Lisa M Verhagen, Liset J de la Fonteyne-Blankestijn, Marieke E Hoonakker, Wim H de Jong

Open access · goldAbstract read
In one paragraph

Article in Particle and fibre toxicology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Toxicity of metal-based nanoparticles: Challenges in the nano era.Frontiers in bioengineering and biotechnology · 2022
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Effects of differently shaped TiOParticle and fibre toxicology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Rob J VandebrielCentre for Health Protection, National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720, BA, Bilthoven, The Netherlands. rob.vandebriel@rivm.nl.ORCID 0000-0001-9140-952X
Jolanda P VermeulenCentre for Health Protection, National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720, BA, Bilthoven, The Netherlands.
Laurens B van EngelenCentre for Health Protection, National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720, BA, Bilthoven, The Netherlands.
Britt de JongCentre for Health Protection, National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720, BA, Bilthoven, The Netherlands.
Lisa M VerhagenIntravacc, PO Box 450, 3720, AL, Bilthoven, The Netherlands.
Liset J de la Fonteyne-BlankestijnCentre for Health Protection, National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720, BA, Bilthoven, The Netherlands.
Marieke E HoonakkerIntravacc, PO Box 450, 3720, AL, Bilthoven, The Netherlands.
Wim H de JongCentre for Health Protection, National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720, BA, Bilthoven, The Netherlands.
National Institute for Public Health and the Environment · NLIntravacc (Netherlands) · NL

Funding

Netherlands Food and Consumer Product Safety Authority V090016
6 · The paper itself

Abstract

backgroundThe use of engineered nanoparticles (NP) is widespread and still increasing. There is a great need to assess their safety. Newly engineered NP enter the market in a large variety; therefore safety evaluation should preferably be in a high-throughput fashion. In vitro screening is suitable for this purpose. TiO

methodsImmature DC were differentiated in vitro from human peripheral blood monocytes. Exposure effects of a series of fourteen TiO

resultsAll NP dispersions contained NP aggregates. The anatase NP and anatase/rutile mixture NP induced a higher CD83 and CD86 expression and a higher IL-12p40 production in vitro than the rutile NP (including coated rutile NP and a rutile NP of a 10-fold larger primary diameter). OVA-specific serum IgE and IgG1 were increased by anatase NP, rutile NP, and CB, in the order rutile<anatase<CB. The three particles similarly increased IL-4 and IL-5 production by bronchial LN cells and eosinophils and lymphocytes in the BALF. Neutrophils were induced by rutile NP and CB but not by anatase NP.

conclusionsOur data show that measuring CD83 and CD86 expression and IL-12p40 and TNF-α production in DC in vitro may provide an efficient way to screen NP for potential adjuvant activity; future studies should establish whether this also holds for other NP. Based on antigen-specific IgE and IgG1, anatase NP have higher adjuvant activity than rutile NP, confirming our in vitro data. Other parameters of the allergic response showed a similar response for the two NP crystal structures. From the viewpoint of safe(r) by design products, rutile NP may be preferred over anatase NP, especially when inhalation exposure can be expected during production or application of the product.

Indexed as

AnimalsBronchoalveolar Lavage FluidCrystallizationDendritic CellsHumansImmunity, CellularImmunoglobulin EImmunoglobulin GInterleukin-4Interleukin-5LungMice, Inbred BALB CNanoparticlesParticle SizeSurface PropertiesTitaniumImmunoglobulin EImmunoglobulin GInterleukin-4Interleukin-5Titaniumtitanium dioxideAdjuvantAnataseDendritic cellInhalationLgELgG1MaturationOvalbuminRutileTitanium dioxide

Identifiers

PMID29382351
PMCPMC5791356
OpenAlexW2794251132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.